Abstracts of Presentations at the 2006 Fall Meeting of the Korean Society of Mycology at the Seoul Kyoyuk Munhwa Hoekwan, Seoul, Korea, October 19–20

Lee, Yong-Bo; Na, Young-Hee; Lim, Chae-Kyu; Jang, In-Hoa; Jang, Dong-Kyoung; Yun, Seong-Eun; Park, Sin-Ae; Lim, Sung-Hee; Cho, Hyeon-Na; Lee, Mi Kyeong; Xiao, Yue-Qin; Lim, Kwang-Mi; Yamamoto, Yoshikazu; Kim, Hyojin; Shin, Myoung‐Sook; Go, Seung-Joo; Cho, Duck-Hyun; Lee, Jin Sung; Jung, Hack Sung; Han, Jae-Gu; Choi, Young-Joon; Hong, Seung‐Beom; Shin, Hyeon-Dong; Kim, Daeho; Jeon, Young-Ah; Go, Seung-Ju; Lee, Jong-Kyu; Hong, Seung-Beom; Choi, Sun-Gyu; Kim, Gyu-Hyun; Lee, Ji Sun; Seo, Ji Young; Hyun, Min Woo; Park, Wook Ha; Kim, Ji Hye; Kim, Jin Su; Lee, Seung Kyu; Kim, Kyung Hee; Ahmed, Imtiaj; Jayasinghe, Chandana; Oh, Ji Yeon; Lee, Hojoung; Ryoo, Mun Il; Park, Sang Hyeon; Paul, Narayan Chandra; Kim, Won Ki; Woo, Sung Kyoon; Jang, Yunwoo; Park, Myung Soo; Yu, Seung Hun; Sim, Mi-Yeong; Lee, Eun-Hwa; Kim, Suk; Lee, Yoo Mee; Eom, Ahn-Heum; Kim, Ki Deok; Kim, Eui Nam; Jee, Sam Nyu; Kim, Jin Hee; Hanh, VU Van; Hong, Suk Il; Kim, Keun; Shin, Keum Chul; Lee, Jong Kyu; Jung, Jong-Gab; Mun, Moo-Hee; Jun, Sang-Cheol; Kim, Kyu-Joong; Kim, Sang Woo; Kim, Young-Jae; Kim, Eun-Jung; Min, Ji-Seon; Lee, Youn-Su; Kim, Seung-Bin; Jung, Mooyoung; Yu, Man-Su; Kim, Dong‐Jun; Youn, Hak-Ro; Han, Sung-Man; Jang, Kye Seung; Yun, Yeo Hong; Yoo, Hun Dal; Jang, Hyo Sun; Lee, Chung Hwa; Ham, Eun-Jeong; Kim, Ho-Kyoung; Kim, Tae‐Woong; Lee, Su‐Young; Ko, Cheol-Soon; Kim, Beom Suk; Lee, Jeo; Han, Sang-Kuk; Lee, Wonho; Shrestha, Bhushan; Sung, Jae-Mo; Kim, Jinju; Chang, Kwang-Joon; Ka, Kang-Hyeon; Hur, Hyeon; Hong, In-Pyo; Shim, Jae-Ouk; Lee, Tae-Soo; Lee, Ji-Yul; Lee, Min-Woong; Yoon, Ji Hwan; Park, Ji Eun; Jo, Hyun Seok; Suh, Dong Yeon; Kim, Seong Hwan; Hong, Seung Beom; Ko, Seung Ju; Luo, Hui; Ren, Mei; Seo, Kwon‐Il; Koh, Young Jin; Hur, Jae–Seoun; Rim, Soon-Ok; Lee, Jin-Hyung; Lee, In-Joong; Rhee, In‐Koo; Kim, Jong-Guk; Ryu, Sun Hwa; Lee, A Young; Sohn, Hee Kyoung; Kim, Myung Kil; Yoon, Ja-Young; Park, Yun‐Hee; Lee, Joong-Keun; Park, Seung-Moon; Yang, Moon-Sik; Uhm, Tai-Boong; Kim, Dae-Hyuk; Kim, In-Yeup; Jang, Kab-Yeul; Jhune, Chang-Sung; Kim, Kwang‐Ho; Yoo, Young Bok; Kong, Won Sik; Jang, Kab Yeul; Kim, In Yeup; Oh, Sejong; Jhune, Chang Sung; Kwon, Hye Jin; Park, Yong Jin; Yoo, Young-Bok; Kong, Won-Sik; Han, Kap-Hoon; Yu, Yeong-Man; Kim, Hyoun-Young; Choi, Mi-Hee; Maeng, Pil-Jae; Kim, Jong Hwa; Chae, Suhn-Kee; Park, Hee-Moon; Chae, Keon‐Sang; Jahng, Kwang-Yeop; Han, Dong-Min; Rukayadi, Yaya; Hwang, Jae-Kwan; Kim, Dong-Gyu; Kim, Sungsoon; Choi, Jun-Oh; Won, Hyokyoung; Bae, Jung Min; Choi, Jung-ah; Moon, Sun-Hwa; Park, Jung‐Bin; Yang, Eunhee; Jin, Young-Hun; Lee, Mi‐Sun; Seo, Mu-Seok; Kim, Gun-A; Kwon, Seok-Tae; Lee, Young-Kyung; Hahn, Bum‐Soo; Kim, Gi-Yong; Sung, Beong-Yeol; Kim, Jong Bum; Yang, Joo-Sung; Rho, Hyun-Su; Lee, Hyun Sook; Lee, Seung Ho; Kim, Sang Beom; Lee, Gun Woo; Shim, Jae Ouk; Shim, Mi Ja; Lee, Min Woong; Lee, U-Youn; Lee, Tae Soo; Lee, Yoon Hee; Lee, Jung Sun; Kim, Hyun Guell; Cho, Kyu Chan; Park, Yong Il; Lee, Wi Young; Ahn, Jin Kwon; Park, Youngki; Ka, Kang Hyeon; Lee, Hyun‐Sook; Ro, Hyeon-Su; Yoon, Jeong Weon; Choi, Sung Woo; Park, Hee Kuk; Yu, Won Jin; Lee, Sung Pil; Juen, Ae Kyung; Kim, Won Woo; Lee, Sang Mong; Park, Namsook; Park, Eunju; Jin, Byung Rae; Kim, Hoon Yub; Kim, Yong Gyun; Seo, Gwan Seuk; Oh, Se Hyun; Kim, Nam Gyu; Kang, Sung Woo; Kim, Jung Bae; Kim, Hong Gi

doi:10.1080/12298093.2006.12016017

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lee W et al (47) recently demonstrated that COVID-19 activates regulatory element binding protein-2 (SREBP-2), a key transcription factory lying at the cross-roads of inflammation modulation and cholesterol biosynthesis. Given the requirement of cholesterol biosynthesis for SARS-CoV-2 buddingdriven exocytosis, any factor modulating SREBP-2 pathway activation may influence the course of COVID-19 disease (47). In this respect, recent findings in human macrophages indicate that anti-apoA-1 IgGs increase the expression of SREBP-2 in a TLR2/4-dependent manner, culminating into enhanced foam cell formation, the hallmark of atherogenesis (33), through anti-apoA-1 IgG-dependent ACAT activation leading to the redirection of cellular cholesterol towards intracellular esterified cholesterol pools and decreased membrane freecholesterol content (33).…”

Section: Perpetuitymentioning

confidence: 99%

SARS-CoV2- infection as a trigger of humoral response against apolipoprotein A-1

Pagano¹,

Yerly²,

Meyer

et al. 2021

Preprint

View full text Add to dashboard Cite

Aims: Unravelling autoimmune targets triggered by SARS-CoV-2 infection may provide crucial insights in the physiopathology of the disease and foster the development of potential therapeutic candidate targets and prognostic tools. We want to determine whether SARS-CoV-2 exposure could trigger a humoral response against apolipoprotein A-1 (anti-apoA-1 IgG) through molecular mimicry and assess its relationship to patient prognosis. Methods and Results: Anti-Spike domain 1 (SD1) IgGs, anti-apoA-1 IgGs and against mimic peptides, as well as cytokines were assessed by immunoassays on a case-control (n=101), an intensive care unit (ICU; n=126) with a 28-days follow-up, and a general population cohort (n=663) with available samples in the pre and post-pandemic period. Linear sequence homologies and antibodies cross-reactivity between apoA-1, TLR2, and Spike epitopes were identified. Overall, anti-apoA-1 IgG levels were higher in COVID-19 patients or anti-SARS-CoV-2 seropositive individuals than in healthy donors or anti-SARS-CoV-2 seronegative individuals (p<0.0001). Significant and similar associations were noted between anti-apoA-1, anti-SARS-CoV-2 IgG, cytokines, and lipid profile. In ICU patients, anti-SARS-CoV-2 and anti-apoA-1 seroconversion rates displayed similar 7-days kinetics, reaching 82% for anti-apoA-1 seropositivity. C-statistics (CS) indicated that anti-Spike/TLR2 mimic-peptide IgGs displayed a significant prognostic accuracy for overall mortality at 28 days (CS: 0.64; p=0.02). In the general population, SARS-CoV-2 exposure increased baseline anti-apoA-1 IgG levels. Conclusions: COVID-19 induces a marked humoral response against the major protein of high-density lipoproteins. As a correlate of poorer prognosis in other clinical settings, such autoimmunity signatures may relate to long-term COVID-19 prognosis assessment and warrant further scrutiny in the current COVID-19 pandemic.

show abstract

Section: Perpetuitymentioning

confidence: 99%

SARS-CoV2- infection as a trigger of humoral response against apolipoprotein A-1

Pagano¹,

Yerly²,

Meyer

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…a h e a d o f p r i n t 2 programs were initiated, Korea shifted its strategyfocus to pursue a step-by-stepgradual recovery strategy [7]. During this periodphase, the spreademergence of the Omicron variant (B.1.1.529) led to a rapid increase in COVID-19 cases [8].…”

Section: E P U Bmentioning

confidence: 99%

“…Omicron variant maximized led to a surge in infections. Because ofDue to its highergreater infectivity and vaccine breakthrough abilitycapacity, the Omicron variant became the relatively dominant COVID-19 variant compared to supplanted the Delta variant as the predominant strain of COVID-19, and the absolutetotal number of infections with the Omicron variant infections has increasedrose [8].…”

Section: E P U B a H E A D O F P R I N Tmentioning

confidence: 99%

Worsening of health disparities across COVID-19 pandemic stages in Korea

Lee,

Nam,

Lee

et al. 2024

Epidemiol Health

View full text Add to dashboard Cite

Objectives: There is a need to examineIn this late stage ofWith the end of the coronavirus disease 2019 (COVID-19) pandemic, the health outcomes of the COVID-19this disease in Korea following the end of pandemic. This studymust be examined. We aimed to examineinvestigate health outcomes and disparities based onlinked to socioeconomic status during the COVID-19 pandemic in Korea, while identifying associated and to identify risk factors for hospitalization and mortality.Methods: This nationwide, retrospective study examined a cohortincorporated an analysis of peopleindividuals with and without COVID-19 in Korea from 1between January 1, 2020 to 31, and December 31, 2022, . The study period was divided into four4 stages. Prevalence (per 100,000),, hospitalization (per 100,000),, mortality (per 100,000),, and case -fatality (per100,000)rates were calculated. per 100,000 population. Multivariate logistic regression was performed to identify risk factors for COVID-19 hospitalization and mortality.Results: Throughout the study periodOverall, the incidence rate was 40,601 per 100,000 population, the mortality rate was 105 per 100,000 population, and the case -fatality rate was 259 per 100,000 cases. There wereA total of 12,577,367 (24.5%) new cases (24.5%) were recorded in stage three,3 and 8,979,635 cases (17.5%) in stage four. The medical aid4.Medical Aid recipients haddisplayed the lowest 3year3-year cumulative incidence rate (32,737 per 100,000),) but the highest hospitalization (5,663 cases per 100,000), mortality (498 per 100,000), and case -fatality (1521 per 100,000).) rates. Male sex, older age, lower economic status, living in non-metropolitan areas, aarea of residence, high Charlson comorbidity index, and individualsdisability were associated with disabilities had a higher E p u ba h e a d o f p r i n t 2 risk of hospitalization and death. Vaccination reduced thewas found to reduce mortality risk of death. Conclusions:As the pandemic progressed, there was a surgesurges were observed in incidence, hospitalization, and mortality, wideningexacerbating disparities related to associated with economic status and disability. Despite these disparitiesNevertheless, Korea has maintained a low case-fatality rate across all economic groups.

show abstract

“…Interestingly, the proposed Avo1 gene contains a 12 nt long SREBP2 binding site (Figure 1 Top). Recently it was found that activated SREBP2 in COVID-19 patients disturbs cholesterol biosynthesis and leads to a cytokine storm [32], therefore the SREBP2 binding site in the Avo1 locus may play an important role in the process of SREBP2 activation and regulation [33]. In addition, cytosine methylation of cytosine-rich Avo1 locus (27.24 %) may play vital roles in SARS-CoV-2 regulation and can serve as a target for possible therapeutic intervention using e.g.…”

Section: Sequence and Position Of Avo1 Locusmentioning

confidence: 99%

Unheeded SARS-CoV-2 proteins? A deep look into negative-sense RNA

Bartas

Volná

Brázda

et al. 2020

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 is a novel ssRNA+ virus from the Coronaviridae family, which has caused the global COVID-19 pandemic. The genome of SARS-CoV-2 is one of the largest of RNA viruses, comprising of 26 known protein-coding loci. This study aimed to explore the coding potential of negative-strand RNA intermediate for its potential to contain additional protein coding-loci. Surprisingly, we have found several putative ORFs and one brandt new functional SARS-CoV-2 protein-coding loci and called it Avo1 (Ambient viral ORF1). This sequence is located on negative-sense RNA intermediate and bona fide coding for 81 amino acid residues long protein and contains strong Kozak sequence for translation on eukaryotic ribosomes. In silico translated protein Avo1 has a predominantly alpha-helical structure. The existence of Avo1 gene is supported also by its evolutionarily and structural conservation in RaTG13 bat coronavirus. The nucleotide sequence of Avo1 also contains a unique SREBP2 binding site which is closely related to the so-called “cytokine storm” in severe COVID-19 patients. Altogether, our results suggest the existence of still undescribed SARS-CoV-2 protein, which may play an important role in the viral lifecycle and COVID-19 pathogenesis.

show abstract

Abstracts of Presentations at the 2006 Fall Meeting of the Korean Society of Mycology at the Seoul Kyoyuk Munhwa Hoekwan, Seoul, Korea, October 19–20

Cited by 4 publications

References 0 publications

SARS-CoV2- infection as a trigger of humoral response against apolipoprotein A-1

SARS-CoV2- infection as a trigger of humoral response against apolipoprotein A-1

Worsening of health disparities across COVID-19 pandemic stages in Korea

Unheeded SARS-CoV-2 proteins? A deep look into negative-sense RNA

Contact Info

Product

Resources

About